MedTrace Logo

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

NCT03712930 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2021-11-17

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate the efficacy of pamiparib in participants with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency (CTC-HRD). All participants will receive pamiparib. The purpose of this study is to demonstrate that pamiparib will improve Objective Response Rate (ORR) and Prostate-Specific Antigen (PSA) response rate

Conditions

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Homologous Recombination Deficiency (HRD)

Interventions

DRUG

Pamiparib

60 mg orally twice daily (BID)

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · Guy's and St Thomas' NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-05
Primary Completion
2020-08-06
Completion
2020-09-02
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Puerto Rico
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03712930 on ClinicalTrials.gov